hVIVO

hVIVO

A rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials.

Founded 1989

London, United Kingdom 248 employees Series B Total: $2.60M Biotechnology, Health Care

is a rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development. The last investment ($2.60M Series B) was made on 13th October 2009 by Aquarius Equity Partners. This United Kingdom-based company has been continuously evolving since its establishment in 1989 and operates in the Biotechnology and Health Care industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$2.60M	1	Aquarius Equity Partners	13 Oct 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

$2.60M

Aquarius Equity Partners

13 Oct 2009

FAQ About hVIVO

A rapidly growing early-stage Contract Research Organisation (CRO) and the global leader in human challenge trials.

hVIVO was founded in 1989.

hVIVO is headquartered in London, United Kingdom.

hVIVO operates in Biotechnology and Health Care. Its work centres on Contract Research Organisation, Clinical Development Services, Human Challenge Trials and Infectious Disease Research.

hVIVO has approximately 248 employees.

hVIVO has completed 1 funding round, raising a total of $2.60M. The latest funding stage is Series B.

Top alternatives and competitors to hVIVO include Novum Pharmaceutical Research Services, Hammersmith Medicines Research Ltd, Nordic Bioscience, Nucleus Network, ViraCor Laboratories. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

hVIVO and Novum Pharmaceutical Research Services are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About hVIVO

Funding Rounds & Investors (1)

hVIVO Alternatives & Competitors

FAQ About hVIVO